High‐Dose Pulse Glucocorticoid Treatment Prevents White Matter Spinal Cord Pseudoatrophy in Newly Diagnosed Multiple Sclerosis
Open Access
- 24 June 2025
- journal article
- Published by Wiley in Annals of Neurology
- Vol. 98 (4) , 837-850
Abstract
Objective: Spinal cord (SC) atrophy correlates with and predicts the underlying progressive biology in active and non‐active multiple sclerosis (MS), thereby providing a biomarker for clinical trials and patient management. Initiation of disease‐modifying therapy (DMT) may be followed by early pronounced central nervous system (CNS) volume loss due to resolution of inflammation (pseudoatrophy) and confounding the interpretation of atrophy. High‐dose glucocorticoids (HDGs) reduce inflammation and might therefore modify pseudoatrophy. Methods: One hundred twenty‐three newly diagnosed and DMT‐naïve MS participants (relapsing–remitting, 70% female participants, median age = 36 years, Expanded Disability Status Scale [EDSS] 2.0) were followed for up to 3 years. Forty‐two participants received HDG before baseline magnetic resonance imaging (MRI; DMT‐HDG; median = 52 days, interquartile range [IQR] = 37–71), whereas 60 did not (DMT/no‐HDG). Twenty‐one participants remained untreated (no‐DMT), and 102 started DMT after baseline MRI. SC total cervical cord cross‐sectional area (TCA), gray matter area (GMA), and white matter area (WMA) and regional brain volumes were analyzed using mixed effects models. Results: The DMT‐HDG, DMT/no‐HDG, and no‐DMT groups had similar demographic, clinical, and radiological features. Pronounced SC pseudoatrophy was observed based on more year 1 versus year 2 volume loss for DMT/no‐HDG (−2.06% vs. 0.83%; P = 0.02) but not DMT‐HDG (−0.51% vs. 0.66%; P = 0.8) and more year 1 volume loss for DMT/no‐HDG compared to DMT‐HDG (−2.06% vs. 0.51%; P = 0.02). Interpretation: HDG preceding baseline MRI suppresses CNS white matter (WM) pseudoatrophy after DMT initiation, most conspicuously for the SC. Suppression of pseudoatrophy with HDG may improve the fidelity of clinical trials and enhance the feasibility for short‐term trials with SC and brain MRI outcomes in active MS by pretreatment with HDG. ANN NEUROL 2025;98:837–850Keywords
Funding Information
- National Institute of Neurological Disorders and Stroke (R01AG038791, R01AG062562, R01NS105741, R35NS111644)
- Valhalla Foundation
- National Institutes of Health (RO1AI170863)
- Race to Erase MS
- Fondazione Italiana Sclerosi Multipla (2019/BC/002)
- National Multiple Sclerosis Society (RG‐1707‐28564)
This publication has 46 references indexed in Scilit:
- Percentage brain volume change in multiple sclerosis mainly reflects white matter and cortical volumeAnnals of Clinical and Translational Neurology, 2022
- Spinal Cord Atrophy Predicts Progressive Disease in Relapsing Multiple SclerosisAnnals of Neurology, 2021
- Dynamics of pseudo‐atrophy in RRMS reveals predominant gray matter compartmentalizationAnnals of Clinical and Translational Neurology, 2021
- Deep gray matter volume loss drives disability worsening in multiple sclerosisAnnals of Neurology, 2018
- Effect of Fingolimod on Brain Volume Loss in Patients with Multiple SclerosisCNS Drugs, 2017
- Spinal cord gray matter atrophy correlates with multiple sclerosis disabilityAnnals of Neurology, 2014
- Clinical Relevance of Brain Volume Measures in Multiple SclerosisCNS Drugs, 2014
- Impact of Fingolimod Therapy on Magnetic Resonance Imaging Outcomes in Patients With Multiple SclerosisArchives of Neurology, 2012
- Localization of grey matter atrophy in early RRMSJournal of Neurology, 2006
- Regional Gray Matter Atrophy in Early Primary Progressive Multiple SclerosisArchives of Neurology, 2006